1 2 3
4 5 UNITED STATES DISTRICT COURT 6 WESTERN DISTRICT OF WASHINGTON AT SEATTLE 7 JAVIER TAPIA, CASE NO. C22-1141-KKE 8
Plaintiff, ORDER DENYING MOTION FOR 9 v. CERTIFICATION
10 NAPHCARE INC., et al.,
11 Defendants.
12 This matter comes before the Court on Defendant NaphCare Inc.’s motion for certification 13 of the Court’s order (Dkt. No. 86 (hereinafter “Order”)) for interlocutory appeal under 28 U.S.C. 14 § 1292(b), and for a stay of the Order pending appeal.1 Dkt. No. 92. Although NaphCare requested 15 oral argument, the Court has reviewed the briefing and the balance of the docket, and finds this 16 matter suitable for disposition on the parties’ briefing.2 For the reasons stated below, NaphCare’s 17 motion is denied. 18 I. FACTS 19 On January 17, 2024, the Court issued the Order, granting in part and denying in part two 20 discovery motions filed by Plaintiff Javier Tapia. In the Order, the Court concluded that 21 22
23 1 The Court previously denied NaphCare’s contemporaneously filed motion for reconsideration of the same order. See Dkt. No. 98.
24 2 This order refers to the parties’ briefing using CM/ECF page numbers. 1 NaphCare’s medical director Dr. Elliot Wade “was not ‘specially employed in anticipation of 2 litigation’ as required to be considered a non-testifying expert under Federal Rule of Civil 3 Procedure 26(b)(4)(D)[.]” Order at 10 (citing Tellabs Operations, Inc. v. Fujitsu Ltd., 283 F.R.D.
4 374, 387 (N.D. Ill. 2012)). And, “[b]ecause Dr. Wade is not such an expert, he can be deposed 5 about what information he reviewed with respect to Tapia and why, along with his opinions and 6 conclusions regarding the care provided by NaphCare, to the extent he has personal knowledge of 7 the same.” Id. (citing Fed. R. Civ. P. 30(c)(2)). 8 NaphCare moves the Court to certify the Order for interlocutory appeal under 28 U.S.C. 9 § 1292(b), “so that the court of appeals can address the important legal question concerning the 10 scope of the attorney-client privilege and the non-testifying expert privilege that is at issue here,” 11 and to stay the Order pending resolution of the appeal. Dkt. No. 92 at 6. Tapia argues this Order 12 does not meet the criteria granting the Ninth Circuit jurisdiction over an appeal at this stage of the
13 case. Dkt. No. 93 at 3–6. 14 II. LEGAL STANDARD 15 “28 U.S.C. § 1292(b) grants the federal courts of appeals jurisdiction over interlocutory 16 appeals when a district court order is entered that would not otherwise be appealable under 28 17 U.S.C. § 1292, and when the district judge finds the order is appropriate for interlocutory appeal.” 18 In re Examination of Privilege Claims, No. MC15-0015-JCC-JPD, 2016 WL 11713117, at *1 19 (W.D. Wash. Jan. 25, 2016). 20 Under § 1292(b), a district court is authorized to certify an order for interlocutory appeal 21 where: (1) there is a “controlling question of law,” (2) there are “substantial grounds for difference 22 of opinion as to that question,” and (3) an immediate resolution of that question “may materially
23 advance the ultimate termination of the litigation.” ICTSI Oregon, Inc. v. Int’l Longshore & 24 Warehouse Union, 22 F.4th 1125, 1130 (9th Cir. 2022) (cleaned up). “Certification under 1 § 1292(b) requires the district court to expressly find in writing that all three § 1292(b) 2 requirements are met.” Couch v. Telescope Inc., 611 F.3d 629, 633 (9th Cir. 2010). 3 “[Section 1292(b)] aims to expedite litigation—a goal that will not be achieved if a party
4 unhappy with an order seeks appellate review at each step of the litigation.” In re Examination of 5 Privilege Claims, 2016 WL 11713117, at *3. Interlocutory appeals are to be certified “only in 6 exceptional situations” where certification will help “avoid protracted and expensive litigation.” 7 In re Cement Antitrust Litig., 673 F.2d 1020, 1026 (9th Cir. 1981); see also Trident Seafoods v. 8 Commonwealth Ins. Co., No. C10-214, 2012 WL 13028551, at *2 (W.D. Wash. Mar. 23, 2012). 9 III. ANALYSIS 10 A. The Order does not concern a controlling question of law. 11 A question need not be dispositive to be a “controlling question of law,” United States v. 12 Woodbury, 263 F.2d 784, 787 (9th Cir. 1959),3 but must be one that will “materially affect the 13 outcome of litigation in the district court.” In re Cement Antitrust Litig., 673 F.2d at 1026. 14 NaphCare argues the Order “involves a new privilege ruling of special consequence, and 15 so[] warrants certification for interlocutory review.” Dkt. No. 92 at 9. NaphCare argues 16 “[r]equiring Dr. Wade—and other in-house experts like him—to disclose a confidential 17 assessment of the case under these circumstances is likely to have a material effect on this and 18 other litigation by diminishing the protections of the attorney-client privilege more generally.” Id. 19 at 9–10. To support this assertion, NaphCare cites Mohawk Indus., Inc. v. Carpenter, 558 U.S. 20 100, 111 (2009), but Mohawk does not support granting certification here. 21 3 In Woodbury, the issue asserted to be a controlling question of law was whether the government was entitled to 22 withhold certain documents under a claim of privilege. 263 F.2d at 787. The court differentiated the government’s claim of privilege from controlling questions of law, stating “the question of privilege which the government now 23 would have us review involves nothing as fundamental as the determination of who are necessary and proper parties, whether a court to which a cause has been transferred has jurisdiction, or whether state or federal law shall be applied.” Id. Because “the claim of privilege here asserted is collateral to the basic issues of this case, [it] cannot be 24 regarded as presenting a ‘controlling question of law’ as those words are used in the statute.” Id. at 788. 1 In Mohawk, the question before the Court was “whether disclosure orders adverse to the 2 attorney-client privilege qualify for immediate appeal under the collateral order doctrine.” 558 3 U.S. at 103. The Court held they do not. Id. In discussing the alternative routes available to
4 parties “confronted with a particularly injurious or novel privilege ruling[,]” the Court observed in 5 dicta that “a party may ask the district court to certify, and the court of appeals to accept, an 6 interlocutory appeal pursuant to 28 U.S.C. § 1292(b).” Id. at 110. The Court did not provide an 7 alternate route for meeting the statutory preconditions for § 1292(b) review, but rather observed 8 that two of the conditions—that the order concerns a “controlling question of law” and that 9 resolution “may materially advance the ultimate termination of the litigation”—are “most likely to 10 be satisfied when a privilege ruling involves a new legal question or is of special consequence[.]” 11 Id. at 110–11 (emphasis added). 12 Even in light of Mohawk, NaphCare must still show that the Order concerns a controlling
13 question of law, a burden it has not met.
Free access — add to your briefcase to read the full text and ask questions with AI
1 2 3
4 5 UNITED STATES DISTRICT COURT 6 WESTERN DISTRICT OF WASHINGTON AT SEATTLE 7 JAVIER TAPIA, CASE NO. C22-1141-KKE 8
Plaintiff, ORDER DENYING MOTION FOR 9 v. CERTIFICATION
10 NAPHCARE INC., et al.,
11 Defendants.
12 This matter comes before the Court on Defendant NaphCare Inc.’s motion for certification 13 of the Court’s order (Dkt. No. 86 (hereinafter “Order”)) for interlocutory appeal under 28 U.S.C. 14 § 1292(b), and for a stay of the Order pending appeal.1 Dkt. No. 92. Although NaphCare requested 15 oral argument, the Court has reviewed the briefing and the balance of the docket, and finds this 16 matter suitable for disposition on the parties’ briefing.2 For the reasons stated below, NaphCare’s 17 motion is denied. 18 I. FACTS 19 On January 17, 2024, the Court issued the Order, granting in part and denying in part two 20 discovery motions filed by Plaintiff Javier Tapia. In the Order, the Court concluded that 21 22
23 1 The Court previously denied NaphCare’s contemporaneously filed motion for reconsideration of the same order. See Dkt. No. 98.
24 2 This order refers to the parties’ briefing using CM/ECF page numbers. 1 NaphCare’s medical director Dr. Elliot Wade “was not ‘specially employed in anticipation of 2 litigation’ as required to be considered a non-testifying expert under Federal Rule of Civil 3 Procedure 26(b)(4)(D)[.]” Order at 10 (citing Tellabs Operations, Inc. v. Fujitsu Ltd., 283 F.R.D.
4 374, 387 (N.D. Ill. 2012)). And, “[b]ecause Dr. Wade is not such an expert, he can be deposed 5 about what information he reviewed with respect to Tapia and why, along with his opinions and 6 conclusions regarding the care provided by NaphCare, to the extent he has personal knowledge of 7 the same.” Id. (citing Fed. R. Civ. P. 30(c)(2)). 8 NaphCare moves the Court to certify the Order for interlocutory appeal under 28 U.S.C. 9 § 1292(b), “so that the court of appeals can address the important legal question concerning the 10 scope of the attorney-client privilege and the non-testifying expert privilege that is at issue here,” 11 and to stay the Order pending resolution of the appeal. Dkt. No. 92 at 6. Tapia argues this Order 12 does not meet the criteria granting the Ninth Circuit jurisdiction over an appeal at this stage of the
13 case. Dkt. No. 93 at 3–6. 14 II. LEGAL STANDARD 15 “28 U.S.C. § 1292(b) grants the federal courts of appeals jurisdiction over interlocutory 16 appeals when a district court order is entered that would not otherwise be appealable under 28 17 U.S.C. § 1292, and when the district judge finds the order is appropriate for interlocutory appeal.” 18 In re Examination of Privilege Claims, No. MC15-0015-JCC-JPD, 2016 WL 11713117, at *1 19 (W.D. Wash. Jan. 25, 2016). 20 Under § 1292(b), a district court is authorized to certify an order for interlocutory appeal 21 where: (1) there is a “controlling question of law,” (2) there are “substantial grounds for difference 22 of opinion as to that question,” and (3) an immediate resolution of that question “may materially
23 advance the ultimate termination of the litigation.” ICTSI Oregon, Inc. v. Int’l Longshore & 24 Warehouse Union, 22 F.4th 1125, 1130 (9th Cir. 2022) (cleaned up). “Certification under 1 § 1292(b) requires the district court to expressly find in writing that all three § 1292(b) 2 requirements are met.” Couch v. Telescope Inc., 611 F.3d 629, 633 (9th Cir. 2010). 3 “[Section 1292(b)] aims to expedite litigation—a goal that will not be achieved if a party
4 unhappy with an order seeks appellate review at each step of the litigation.” In re Examination of 5 Privilege Claims, 2016 WL 11713117, at *3. Interlocutory appeals are to be certified “only in 6 exceptional situations” where certification will help “avoid protracted and expensive litigation.” 7 In re Cement Antitrust Litig., 673 F.2d 1020, 1026 (9th Cir. 1981); see also Trident Seafoods v. 8 Commonwealth Ins. Co., No. C10-214, 2012 WL 13028551, at *2 (W.D. Wash. Mar. 23, 2012). 9 III. ANALYSIS 10 A. The Order does not concern a controlling question of law. 11 A question need not be dispositive to be a “controlling question of law,” United States v. 12 Woodbury, 263 F.2d 784, 787 (9th Cir. 1959),3 but must be one that will “materially affect the 13 outcome of litigation in the district court.” In re Cement Antitrust Litig., 673 F.2d at 1026. 14 NaphCare argues the Order “involves a new privilege ruling of special consequence, and 15 so[] warrants certification for interlocutory review.” Dkt. No. 92 at 9. NaphCare argues 16 “[r]equiring Dr. Wade—and other in-house experts like him—to disclose a confidential 17 assessment of the case under these circumstances is likely to have a material effect on this and 18 other litigation by diminishing the protections of the attorney-client privilege more generally.” Id. 19 at 9–10. To support this assertion, NaphCare cites Mohawk Indus., Inc. v. Carpenter, 558 U.S. 20 100, 111 (2009), but Mohawk does not support granting certification here. 21 3 In Woodbury, the issue asserted to be a controlling question of law was whether the government was entitled to 22 withhold certain documents under a claim of privilege. 263 F.2d at 787. The court differentiated the government’s claim of privilege from controlling questions of law, stating “the question of privilege which the government now 23 would have us review involves nothing as fundamental as the determination of who are necessary and proper parties, whether a court to which a cause has been transferred has jurisdiction, or whether state or federal law shall be applied.” Id. Because “the claim of privilege here asserted is collateral to the basic issues of this case, [it] cannot be 24 regarded as presenting a ‘controlling question of law’ as those words are used in the statute.” Id. at 788. 1 In Mohawk, the question before the Court was “whether disclosure orders adverse to the 2 attorney-client privilege qualify for immediate appeal under the collateral order doctrine.” 558 3 U.S. at 103. The Court held they do not. Id. In discussing the alternative routes available to
4 parties “confronted with a particularly injurious or novel privilege ruling[,]” the Court observed in 5 dicta that “a party may ask the district court to certify, and the court of appeals to accept, an 6 interlocutory appeal pursuant to 28 U.S.C. § 1292(b).” Id. at 110. The Court did not provide an 7 alternate route for meeting the statutory preconditions for § 1292(b) review, but rather observed 8 that two of the conditions—that the order concerns a “controlling question of law” and that 9 resolution “may materially advance the ultimate termination of the litigation”—are “most likely to 10 be satisfied when a privilege ruling involves a new legal question or is of special consequence[.]” 11 Id. at 110–11 (emphasis added). 12 Even in light of Mohawk, NaphCare must still show that the Order concerns a controlling
13 question of law, a burden it has not met. Neither in its motion nor in its reply does NaphCare 14 articulate how the Order materially affects the outcome of the present litigation. See In re Cement 15 Antitrust Litig., 673 F.2d at 1026. The issue in this case is whether NaphCare provided 16 constitutionally inadequate medical care to Tapia, not whether NaphCare’s medical director can 17 be retroactively cast as a non-testifying expert halfway through his deposition. The closest 18 NaphCare comes to identifying an issue of law is asserting that the Order “is likely to have a 19 material effect on this … litigation by diminishing the protections of the attorney-client 20 privilege[.]” Dkt. No. 92 at 9–10. NaphCare does not, however, explain how this alleged 21 diminishment is material to the outcome of this litigation. Accordingly, the Court finds NaphCare 22 has not met its burden, and its motion therefore fails. Couch, 611 F.3d at 633 (parties seeking
23 interlocutory appeal under § 1292(b) must satisfy all three requirements). 24 1 B. There is no substantial ground for differences of opinion. 2 Even if the matter involved a controlling question of law, which it does not, NaphCare 3 must also show the controlling question of law involves an issue for which substantial ground for
4 difference of opinion exists. In re Examination of Privilege Claims, 2016 WL 11713117, at *3. 5 Again, NaphCare fails. 6 NaphCare argues “the Court’s order effectively narrowed the scope of the [non-testifying 7 expert] privilege to exclude in-house experts from its ambit.” Dkt. No. 92 at 10. NaphCare asserts 8 that “courts disagree about whether in-house experts can ever benefit” from “the non-testifying 9 expert privilege of Rule 26(b)(4)(D).” Id. at 10. In support of this claim, NaphCare cites mixed 10 authority on the issue. See id. (comparing Virginia Elec. & Power Co. v. Sun Shipbuilding & Dry 11 Dock Co., 68 F.R.D. 397, 408 (E.D. Va. 1975) (finding in-house expert did not come under Rule 12 26(b)(4)(D)), with In re Shell Oil Refinery, 132 F.R.D. 437, 441 (E.D. La. 1990), clarified by, 134
13 F.R.D. 148, 150 (E.D. La. 1990) (finding in-house experts did come under Rule26(b)(4)(D))). 14 Tapia responds that none of the cases cited by NaphCare contradict the Order: “To the 15 contrary, there is agreement amongst the federal judiciary that ‘[w]hether an in-house expert is 16 retained or specially employed must be decided case-by-case’—which is exactly what the Court 17 did here.” Dkt. No. 93 at 5 (quoting In re Shell Oil Refinery, 132 F.R.D. at 442). 18 To determine whether a “substantial ground for difference of opinion” exists under 19 § 1292(b), “courts must examine to what extent controlling law is unclear.” In re Examination of 20 Privilege Claims, 2016 WL 11713117, at *3 (citing Couch, 611 F.3d at 633). “A substantial 21 ground for difference of opinion is often established by a dearth of precedent within the controlling 22 jurisdiction and conflicting decisions in other circuits.” APCC Servs., Inc. v. AT & T Corp., 297
23 F. Supp. 2d 101, 107 (D.D.C. 2003). “[J]ust because counsel contends that one precedent rather 24 than another is controlling does not mean there is a substantial difference of opinion as will support 1 an interlocutory appeal.” Couch, 611 F.3d at 633 (quoting 3 FEDERAL PROCEDURE, LAWYERS 2 EDITION § 3:212 (2010)). 3 Here, NaphCare’s motion fundamentally misconstrues the Order. The Court did not
4 broadly pronounce that in-house experts are categorically excluded from the protection of Rule 5 26(b)(4)(D) in all cases. Rather, the Court acknowledged inconsistent precedent on the topic 6 across federal courts, and examined the evidence before it to determine if Dr. Wade was “specially 7 employed” for this litigation. Order at 9. Based on the record in this case, including but not limited 8 to the facts that Dr. Wade routinely reviews medical care provided to inmates as a component of 9 his regular employment, that he provided his opinion directly to NaphCare employees and not 10 counsel, and that he was produced for deposition without objection, the Court concluded that in 11 this instance, NaphCare had not shown that Dr. Wade was “specially employed” as required by 12 the Rule. The cases cited by NaphCare do not demonstrate a substantial ground for difference of
13 opinion exists, rather, NaphCare merely disagrees with the Court’s application of the mixed, fact- 14 specific precedent to this particular case. Accordingly, NaphCare has not met the second 15 requirement for appeal under § 1292(b). 16 C. Immediate appeal will not advance the ultimate determination of this matter. 17 The Court need not examine the third prong in great detail because the first two prongs are 18 not met. See 28 U.S.C. § 1292(b). However, the third prong also supports denial of NaphCare’s 19 motion. This matter has been pending since March 2021 (Dkt. No. 61-16), and “[c]ertification of 20 interlocutory appeal will only add further delay in this litigation.” In re Examination of Privilege 21 Claims, 2016 WL 11713117, at *4. 22
23 24 1 IV. CONLUSION 2 For the reasons stated above, the Court DENIES NaphCare’s motion (Dkt. No. 92). 3 Dated this 21st day of March, 2024.
4 5 A 6 Kymberly K. Evanson United States District Judge 7
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24